
William Y. Lee
Examiner (ID: 19406)
| Most Active Art Unit | 1629 |
| Art Unit(s) | 1629, 1623 |
| Total Applications | 852 |
| Issued Applications | 350 |
| Pending Applications | 117 |
| Abandoned Applications | 407 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18434128
[patent_doc_number] => 20230181422
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => DRY POWDER INHALATION DRUG PRODUCTS EXHIBITING MOISTURE CONTROL PROPERTIES AND METHODS OF ADMINISTERING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/981673
[patent_app_country] => US
[patent_app_date] => 2022-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12238
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17981673
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/981673 | DRY POWDER INHALATION DRUG PRODUCTS EXHIBITING MOISTURE CONTROL PROPERTIES AND METHODS OF ADMINISTERING THE SAME | Nov 6, 2022 | Pending |
Array
(
[id] => 19497560
[patent_doc_number] => 20240336578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => NOVEL SALT OF 2-AMINO-2-(2-(1-DECYL-1H-1,2,3-TRIAZOL-4-YL)ETHYL)PROPANE-1,3-DIOL, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
[patent_app_type] => utility
[patent_app_number] => 18/688333
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10039
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18688333
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/688333 | Salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol, and pharmaceutical composition containing same | Nov 3, 2022 | Issued |
Array
(
[id] => 18449473
[patent_doc_number] => 20230190749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => TREATMENT OF BRAIN CANCER
[patent_app_type] => utility
[patent_app_number] => 17/975709
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975709
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/975709 | TREATMENT OF BRAIN CANCER | Oct 27, 2022 | Pending |
Array
(
[id] => 18468684
[patent_doc_number] => 20230202966
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => ACYCLIC LIPIDS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/972395
[patent_app_country] => US
[patent_app_date] => 2022-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 132070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17972395
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/972395 | Acyclic lipids and methods of use thereof | Oct 23, 2022 | Issued |
Array
(
[id] => 18193587
[patent_doc_number] => 20230047106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT
[patent_app_type] => utility
[patent_app_number] => 17/969638
[patent_app_country] => US
[patent_app_date] => 2022-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17969638
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/969638 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT | Oct 18, 2022 | Pending |
Array
(
[id] => 18211621
[patent_doc_number] => 20230057884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => CO-CRYSTALS OF TRAMADOL AND COXIBS
[patent_app_type] => utility
[patent_app_number] => 17/968253
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9095
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968253
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/968253 | CO-CRYSTALS OF TRAMADOL AND COXIBS | Oct 17, 2022 | Pending |
Array
(
[id] => 20491505
[patent_doc_number] => 12533360
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Inhibition of BRD proteins suppresses the phenotype of uterine fibroids
[patent_app_type] => utility
[patent_app_number] => 17/968403
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 34
[patent_no_of_words] => 0
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968403
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/968403 | Inhibition of BRD proteins suppresses the phenotype of uterine fibroids | Oct 17, 2022 | Issued |
Array
(
[id] => 19125626
[patent_doc_number] => 20240130979
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/046125
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13310
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046125
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046125 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN CONDITIONS | Oct 11, 2022 | Pending |
Array
(
[id] => 18297742
[patent_doc_number] => 20230107428
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => 23-O-ACETYLALISOL B AS A NOVEL THERAPEUTIC AGENT FOR CORONAVIRUS INDUCED SEVERE ACUTE RESPIRATORY SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/936179
[patent_app_country] => US
[patent_app_date] => 2022-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936179
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/936179 | 23-O-ACETYLALISOL B AS A NOVEL THERAPEUTIC AGENT FOR CORONAVIRUS INDUCED SEVERE ACUTE RESPIRATORY SYNDROME | Sep 27, 2022 | Pending |
Array
(
[id] => 18707527
[patent_doc_number] => 20230330103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/932914
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 465
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/932914 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Sep 15, 2022 | Pending |
Array
(
[id] => 20005877
[patent_doc_number] => 20250144099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-08
[patent_title] => INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/690228
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18690228
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/690228 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | Sep 7, 2022 | Pending |
Array
(
[id] => 19001915
[patent_doc_number] => 20240065986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => OPTIMIZED INGREDIENT MATRICES FOR ENHANCED HYDRATION AND MUSCLE RECOVERY PRE-, INTRA-, AND POST-EXERCISE
[patent_app_type] => utility
[patent_app_number] => 17/900405
[patent_app_country] => US
[patent_app_date] => 2022-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17900405
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/900405 | OPTIMIZED INGREDIENT MATRICES FOR ENHANCED HYDRATION AND MUSCLE RECOVERY PRE-, INTRA-, AND POST-EXERCISE | Aug 30, 2022 | Abandoned |
Array
(
[id] => 19001920
[patent_doc_number] => 20240065991
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => COMPOSITIONS OF 1,3-BUTANEDIOL AND BETA-HYDROXYBUTYRIC ACID TO PROVIDE OPTIMAL THERAPEUTIC KETOSIS
[patent_app_type] => utility
[patent_app_number] => 17/822727
[patent_app_country] => US
[patent_app_date] => 2022-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822727
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/822727 | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis | Aug 25, 2022 | Issued |
Array
(
[id] => 18091262
[patent_doc_number] => 20220409603
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => OPHTHALMIC COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/894882
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894882
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894882 | OPHTHALMIC COMPOSITION | Aug 23, 2022 | Pending |
Array
(
[id] => 18091263
[patent_doc_number] => 20220409604
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => OPHTHALMIC COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/894884
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49289
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894884
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894884 | OPHTHALMIC COMPOSITION | Aug 23, 2022 | Pending |
Array
(
[id] => 18091264
[patent_doc_number] => 20220409605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => OPHTHALMIC COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/894885
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49417
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894885
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894885 | OPHTHALMIC COMPOSITION | Aug 23, 2022 | Pending |
Array
(
[id] => 20193517
[patent_doc_number] => 20250270227
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/684477
[patent_app_country] => US
[patent_app_date] => 2022-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32166
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18684477
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/684477 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Aug 18, 2022 | Pending |
Array
(
[id] => 18036154
[patent_doc_number] => 20220380369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => CYTISINE SALTS
[patent_app_type] => utility
[patent_app_number] => 17/877216
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877216
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/877216 | Cytisine salts | Jul 28, 2022 | Issued |
Array
(
[id] => 18296183
[patent_doc_number] => 20230105869
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => C5aR INHIBITOR REDUCTION OF URINARY sCD163
[patent_app_type] => utility
[patent_app_number] => 17/815992
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9443
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815992
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815992 | C5aR INHIBITOR REDUCTION OF URINARY sCD163 | Jul 28, 2022 | Pending |
Array
(
[id] => 17988771
[patent_doc_number] => 20220354808
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS
[patent_app_type] => utility
[patent_app_number] => 17/874522
[patent_app_country] => US
[patent_app_date] => 2022-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9836
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17874522
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/874522 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | Jul 26, 2022 | Pending |